Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

461
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
461
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

592
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
592
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

978
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
978
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

1.5K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.5K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

1.2K
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.2K
Dialysis01:27

Dialysis

2.0K
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

JAMA network open·2022
Same author

Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study.

Rheumatology (Oxford, England)·2022
Same author

Antiphospholipid syndrome: the burden of inadequate anticoagulation management.

Clinical and experimental rheumatology·2022
Same author

Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual.

Arthritis care & research·2022
Same author

Optimising ANCA-associated vasculitis management and infectious risks during the COVID-19 pandemic.

Clinical and experimental rheumatology·2022
Same author

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry.

RMD open·2022

Related Experiment Video

Updated: Apr 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Scleroderma Renal Crisis.

Loïc Guillevin1, Luc Mouthon1

  • 1Department of Internal Medicine, Centre de Référence Maladies Systémiques et Auto-Immunes Rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France.

Rheumatic Diseases Clinics of North America
|July 27, 2015
PubMed
Summary

Scleroderma renal crisis (SRC) is a severe complication of systemic sclerosis (SSc). Early diagnosis and treatment with ACE inhibitors improve outcomes for this rare condition.

Keywords:
Acute renal failureAngiotensin-converting-enzyme inhibitorsArterial hypertensionScleroderma renal crisisSystemic sclerosis

More Related Videos

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

5.0K
Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury
07:03

Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury

Published on: February 15, 2022

1.8K

Related Experiment Videos

Last Updated: Apr 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

5.0K
Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury
07:03

Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury

Published on: February 15, 2022

1.8K

Area of Science:

  • Nephrology
  • Rheumatology
  • Internal Medicine

Background:

  • Scleroderma renal crisis (SRC) is a serious, albeit rare, complication of systemic sclerosis (SSc).
  • The condition presents significant challenges in diagnosis and management, impacting patient prognosis.
  • Understanding the epidemiology and clinical course of SRC is crucial for improving patient care.

Purpose of the Study:

  • To highlight the critical importance of prompt recognition and management of scleroderma renal crisis.
  • To emphasize the role of angiotensin-converting-enzyme inhibitors in achieving favorable outcomes.
  • To underscore the need for further research into the prevalence and disparities of systemic sclerosis.

Main Methods:

  • This abstract is based on a review of current literature and clinical guidelines regarding scleroderma renal crisis and systemic sclerosis.
  • Key findings on diagnosis, treatment, and outcomes were synthesized.
  • Epidemiological data and prevalence disparities were considered.

Main Results:

  • Scleroderma renal crisis is a severe manifestation of systemic sclerosis.
  • Early detection and immediate treatment with angiotensin-converting-enzyme inhibitors are associated with the best patient outcomes.
  • The prevalence of systemic sclerosis is not well-established and varies geographically.

Conclusions:

  • Prompt identification and intervention are paramount for managing scleroderma renal crisis effectively.
  • Angiotensin-converting-enzyme inhibitors represent the cornerstone of therapy for SRC.
  • Further epidemiological studies are needed to address the known disparities in SSc prevalence.